HRTX Q1 2022 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M+17.2% YoY

Gross Profit

$12M51.6% margin

Operating Income

-$63M-268.2% margin

Net Income

-$64M-272.4% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

+13.6%

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$45M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$274M

Total Liabilities

$250M

Stockholders' Equity

$24M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$20M	+17.2%
Gross Profit	$12M	$11M	+11.9%
Operating Income	-$63M	-$52M	-20.7%
Net Income	-$64M	-$53M	-21.4%

Revenue Segments

C I N V A N T I

$20M86%

S U S T O L

$2M9%

Z Y N R E L E F

$1M5%